Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
Hajjar I, Okafor M, Wan L, Yang Z, Nye J, Bohsali A, Shaw L, Levey A, Lah J, Calhoun V, Moore R, Goldstein F. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease. Brain Communications 2022, 4: fcac270. PMID: 36440097, PMCID: PMC9683395, DOI: 10.1093/braincomms/fcac270.Peer-Reviewed Original ResearchProdromal Alzheimer's diseaseMild cognitive impairmentCognitive effectsCognitive functionCognitive impairmentNon-hypertensive individualsAlzheimer's diseasePositive cognitive effectsAssociated with improved executive functionComposite cognitive scoreGlobal cognitive functionFunctional network connectivityImproving global cognitive functionBrain amyloid accumulationExecutive functionExploratory outcomesCognitive measuresSubcortical networksHippocampal volumeNon-hypertensive adultsFalse discovery rate correctionParahippocampal regionIntention-to-treat approachPlacebo-controlled trialNon-hypertensive participants